B. D. Lichty, C. J. Breitbach, D. F. Stojdl, and J. C. Bell, Going viral with cancer immunotherapy, Nat Rev Cancer, vol.14, pp.559-567, 2014.

R. Andtbacka, H. L. Kaufman, F. Collichio, T. Amatruda, and N. Senzer, Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma, J Clin Oncol, 2015.

R. H. Andtbacka, M. Ross, I. Puzanov, M. Milhem, and F. Collichio, Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial, Ann Surg Oncol, vol.23, pp.4169-4177, 2016.

K. M. Kreamer, Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer, J Adv Pract Oncol, vol.5, pp.418-431, 2014.

I. Puzanov, M. M. Milhem, D. Minor, O. Hamid, and A. Li, Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma, J Clin Oncol, vol.34, pp.2619-2626, 2016.

J. Pol, N. Bloy, F. Obrist, A. Eggermont, and J. Galon, Trial Watch:: Oncolytic viruses for cancer therapy, Oncoimmunology, vol.3, 2014.

, Editorial Open Access Immunother Open Acc, an open access journal, vol.2, pp.2471-9552

. Fonteneau, Immunotherapy (Los Angel), vol.2, p.4, 2016.

, Immunotherapy: Open Access Immu n o th e ra py: Op e n A cc ess ISSN, pp.2471-9552

J. Pol, Trial Watch-Oncolytic viruses and cancer therapy, Oncoimmunology, vol.5, p.1117740, 2016.

E. Vacchelli, A. Eggermont, C. Sautès-fridman, J. Galon, and L. Zitvogel, Trial watch: Oncolytic viruses for cancer therapy, Oncoimmunology, vol.2, p.24612, 2013.

A. Marchini, . Scott, and J. Rommelaere, Overcoming Barriers in, 2016.

, Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade, Viruses, vol.8, p.9

, Oncolytic Viruses and Immune Checkpoint Inhibitors, Citation: Fonteneau JF, vol.2, p.105, 2016.